Truth in Advertising, the nonprofit consumer group known as TINA.org, on November 18, 2026, published complaints it had sent a day earlier, on November 17, to the Federal Trade Commission, the U.S. Food and Drug Administration, the New York State Attorney General and New York City's Department of Consumer and Worker Protection, asking all four to investigate the marketing of Ultra, a Brooklyn start-up that sells nicotine-free "focus" pouches with the line "like if Zyn and Adderall had a baby."

In Short

A consumer group has asked U.S. federal and New York regulators to investigate Ultra, a company that sells mouth pouches it pitches as a nicotine-free, prescription-free way to focus. The group says Ultra markets the pouch as an ADHD treatment and Adderall substitute without FDA approval or proper science, aims ads at minors, encourages use beyond its own label limits and signs buyers up for subscriptions that are hard to cancel. These are allegations in letters, not findings by any regulator, and the company did not respond when TINA.org asked for comment. For advertisers, the evidence in the complaint reads like a map of where the ads ran: Google sponsored products on a search about a teen with ADHD, YouTube ads before student videos, Instagram stories, paid athletes and promoters paid by commission.

What TINA.org is asking for

The two letters are short on demands and long on exhibits. The federal complaint runs to 31 pages of argument and screenshots plus 20 pages of footnotes, with 104 numbered citations. The letter to New York officials is two pages long and attaches the federal complaint, noting that the company's practices "raise serious concerns under New York state and city laws."

Both letters open with the same charge. According to TINA.org, Nuro Pouches, Inc., doing business as Ultra, Inc., "is advertising its oral pouches as a treatment for Attention-Deficit/Hyperactivity Disorder (ADHD), a substitute for prescription medication, and a source of instant focus and mental clarity, all without competent and reliable substantiation or FDA approval." The letters close by asking the agencies to "investigate and take appropriate enforcement action."

The letters were signed by Laura Smith, TINA.org's legal director, and Bonnie Patten, its executive director. Ultra was copied by email, with its Brooklyn address, 25 Kent Ave., listed on both letters.

Who received the complaints

Recipient Office Named addressee Laws cited by TINA.org
Federal Trade Commission Bureau of Consumer Protection Chris Mufarrige, Director; Brian Shull, Acting Associate Director Section 5 of the FTC Act (15 U.S.C. 45); Restore Online Shoppers' Confidence Act (15 U.S.C. 8403)
U.S. Food and Drug Administration Office of Compliance and Enforcement, Human Foods Program Ann Oxenham, Director 21 U.S.C. 331(d) and 355(a) (unapproved new drugs); 21 U.S.C. 321(ff) and 321(g)(1)(C); 21 C.F.R. 101.93(g)(2)
New York State Attorney General Bureau of Consumer Frauds and Protection Jane Azia, Bureau Chief N.Y. Gen. Bus. Law 349, 350 and 527-a
New York City Department of Consumer and Worker Protection Commissioner's office Samuel A.A. Levine, Commissioner N.Y.C. Rules, title 6, 5-110 to 5-110.3

TINA.org has published a database page for the company with three evidence sets, titled "Ultra Checkout Process," "Ultra Health Claims" and "Ultra Reckless Marketing." According to the complaint, the health-claims set holds more than 100 examples and the reckless-marketing set more than 40.

Nothing in the published record shows that any of the four agencies has opened an investigation. A complaint from an advocacy group carries no legal finding. The FTC and the FDA are free to act on such letters, to ignore them or to fold them into existing work without saying so. TINA.org has used this route for years: in 2016, it filed an FTC complaint over undisclosed Kardashian and Jenner Instagram posts after a warning letter to the family and more than two dozen brands.

The company and its product

Ultra launched in May 2025, according to the company's funding announcement, and says it sold 1,000,000 cans within its first six months, "making it the #1 nicotine-free pouch brand in the world." On January 20, 2026, Ultra announced an $11 million Series A round. A correction issued on January 21 changed the last sentence of the first paragraph to read: "The round was led by Left Lane Capital, with participation from top CPG founders such as Harry's, Grüns, and Rockstar Energy."

The corrected release does not name any athletes as investors. TINA.org's article and complaint say the backers include NFL quarterbacks Joe Burrow and Dak Prescott; the complaint's sources for that are posts by a venture-capital news account on January 20, 2026, a Vice article and a Prescott Facebook post dated November 2, 2026.

According to the release, the money was to "expand hiring across the United States, broaden distribution into retail, and advance their product roadmap, including new formats and strength/profile extensions over time." The complaint, citing an Athletech News report, says Ultra plans to sell in convenience stores and at retailers like Walmart and Target. For now, according to TINA.org, the pouches are sold online only: on Ultra's website, on Amazon, on TikTok Shop and on Faire.

The release framed the market in large numbers. It said the oral pouch category was led by the nicotine segment, "which analysts estimate reached about $5.4B in global sales in 2024 and could reach roughly $25B by 2030 - nearly 30% CAGR," without naming the analysts. It also stated that "roughly 30% of buyers reported they had never used nicotine products." TINA.org quotes that same sentence back at the company, arguing in a footnote that the marketing "may introduce the pouch habit to young people who have never used pouches."

Eric Drymer, founder and chief executive, described the origin of the business in the release. "This business started with my own story - like many of my friends, I switched to pouches after listening to Huberman and learning about the research on nicotine's cognitive benefits," he said. "But nicotine is still so addictive, and I didn't want to sacrifice my long-term health for short-term focus. Ultra exists to give consumers a clean, guilt-free focus in the form factor they love."

Harley Miller, chief executive and managing partner at Left Lane Capital, said in the same release that "while some customers use Ultra as a step-down option as they reduce nicotine intake, Ultra is also attracting consumers who never used nicotine products in the first place."

The three pouches

Product What it contains, per the documents How Ultra pitches it Limits stated by Ultra
Focus Pouch 100 mg Enfinity paraxanthine, 30 mg Alpha GPC, 10 mg L-theanine, 1 mg ginseng extract, 2 mg vitamin B6, 2 mg vitamin B12, 7.68 mg sodium; 15 pouches per can "When your afternoon needs precision - deep work, training, a big meeting - pop a Focus pouch for razor-sharp cognition without the jittery edge." Label: "Limit to 4 servings per day." Product page: "Do not exceed 4 Pouches per day."
Energy Pouch 180 mg caffeine, among other ingredients (per TINA.org) "Replace your coffee with a clean energy pouch." Ultra's FAQ, per TINA.org: "not recommend exceeding 2 pouches per day" (360 mg), "per FDA guidelines"; intended only for adults
Sleep Pouch Melatonin and "5 calming adaptogens" "Fall asleep faster with clinically-dosed melatonin + 5 calming adaptogens." Not stated in the documents

The Focus Pouch was the launch product. An Ultra social post reproduced in the complaint says an "upgraded formula now packs 100mg of Paraxathine (up from 75mg of Paraxathine)," with the ingredient name misspelled in the original. The pouches come in Blue Razz, Watermelon, Tropical, Cool Mint, Wintergreen, Sweet Mint and Black Cherry.

One detail in the record has shifted with the product range. The January release described Ultra as "a nicotine-free, caffeine-free functional pouch brand" whose pouches "intentionally avoid nicotine and caffeine." The Energy Pouch, added later, contains 180 mg of caffeine, according to TINA.org, and the complaint argues that its canister "looks remarkably similar" to the Focus canister.

The ads in Ultra's own words

The complaint rests on quotation. The table below records the wording TINA.org challenges, with the channel and date where the complaint gives one.

Wording (verbatim) Where it ran Date given
"Dude, this is like if Zyn and Adderall had a baby." YouTube ad "Guilt-free focus in a pouch," more than 32 million views Posted October 20, 2025
"IF ADDERALL AND ZYN HAD A BABY / Minus The Baggage" "Ultra Pouches for Focus" YouTube ad July 19, 2026
"ADDERALL NEEDS A PRESCRIPTION. THIS DOESN'T." Instagram story ads Recorded by TINA.org October 24 and 31, 2026
"Adderall without the noise." YouTube Short February 23, 2026
"I used to bring Adderall with me on trips. Yeah not ideal. ... ULTRA is literally the only thing that lets me switch modes fast." YouTube Short January 5, 2026
"try a natural alternative that'll get you locked in like the Adderall but won't f*** your sleep" Instagram Reel, co-founder Nicola Cantini with a student January 11, 2026
"Experience immediate, intense focus from a clinically proven formula of research-grade nootropics + adaptogens in as little as 5 minutes." Ultra website Not given
"Clinically proven to enhance cognition and productivity with fewer side effects and a 25% shorter half-life vs. caffeine." Ultra website Not given
"Hits your system faster than coffee to silence hunger hormones and ignite mental clarity within 15-30 minutes" Ultra website Not given
"Ultra Focus on Demand" Banner ad Recorded by TINA.org October 18, 2026
"YOUR UNFAIR ADVANTAGE ... DESIGNED TO SHARPEN YOUR MIND" Ultra Amazon store Not given
"Support weight loss with proven appetite suppression that won't break your fast." Meta ad August 6, 2026

The "Zyn" in the pitch is the leading nicotine pouch brand. Adderall is a prescription stimulant approved by the FDA to treat ADHD. One version of the prescription ad adds the labels "DRUG-FREE," "SHARP IN 5 MINUTES" and "ZERO NICOTINE." TINA.org's article puts the strategy plainly: "Ultra doesn't bury its Adderall marketing comparison. It headlines it."

The company's own homepage, as it stood on November 18, opens with "INSTANT FOCUS IN A POUCH" and "A NEXT GENERATION TOOL TO RECLAIM CONTROL OF YOUR FOCUS AND ENERGY." It tells visitors to "POP 1-2 ULTRA FOCUS POUCHES," "FEEL INTENSE FOCUS IN 5-10 MIN" and expect "EFFECTS LAST 1-2 HOURS." Its footer carries the standard supplement disclaimer: "These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease."

Drug or supplement: the regulatory theory

The FDA part of the complaint turns on a definition. Ultra labels the Focus Pouch with a "Supplement Facts" panel. Under federal law, a dietary supplement must be "intended for ingestion," and TINA.org argues that a pouch held between gum and lip, with a label that says "Do not swallow pouch," is not.

The complaint quotes an FDA warning letter to McDaniel Water LLC from September 7, 2021: "Topical products and products intended to enter the body through the skin or mucosal tissues are not dietary supplements." It quotes Ultra's own FAQ to establish the route of absorption: "The tingle is normal and a sign the ingredients are activating. It typically fades within a few minutes of placement and means absorption is underway."

If the pouch is not a supplement, TINA.org says, it cannot use the supplement exemption for structure and function claims, and any such claim turns it into a drug that needs FDA approval. The group goes further on ADHD: "Claiming that a product can treat ADHD or replace Adderall is a disease claim that renders it a drug requiring FDA approval."

To show that focus and memory claims have triggered FDA action before, the complaint cites warning letters to TEK Naturals (February 5, 2019), Peak Nootropics (February 5, 2019), NV Nutrition and VitaCig (both December 1, 2021) and, most recently, Beach Weekend Management LLC, trading as Nic and Jet Fuel, on February 5, 2026. The TEK Naturals letter cited a product sold as "a safe and highly effective alternative to Adderall."

Ultra's position, as far as its public pages state it, is the disclaimer in its footer, and its ads call the product "DRUG-FREE." The classification is for the FDA to decide; neither the company's label nor TINA.org's letter settles it.

The paraxanthine question

The Focus Pouch is built around paraxanthine, sold under the Enfinity brand by Ingenious Ingredients, L.P., according to the complaint. Ultra's FAQ answers the caffeine question this way: "No nicotine, no tobacco, no caffeine. Instead of caffeine, we use Enfinity® Paraxanthine - a naturally occurring metabolite of caffeine that delivers focus and alertness with less likelihood of jitters, anxiety, or sleep disruption. It also clears from your system faster than caffeine."

TINA.org disputes the distinction. It describes paraxanthine as "a central nervous system stimulant and caffeine's primary metabolite" that "functions much like caffeine." It calls the ingredient in Ultra's pouch synthetic and states that "Paraxanthine does not occur naturally," citing a 1986 study by A. Lelo and colleagues in the British Journal of Clinical Pharmacology. The same study reported mean half-lives of 4.1 hours for caffeine and 3.1 hours for paraxanthine, which the authors described as "similar in value," with no statistically significant difference, according to the complaint.

Ultra's own figures for the gap differ by page. One web panel claims "a 25% shorter half-life vs. caffeine." An "Intro Offer" page, as recorded by TINA.org on November 6, 2026, claims a "40% Shorter half-life of Enfinity® PX as compared to caffeine."

TINA.org then converts the dose. The body turns about 70% to 80% of ingested caffeine into paraxanthine, and caffeine's molecule weighs about 7.8% more (194.19 g/mol against 180.16 g/mol). On that basis, according to the complaint, 100 mg of paraxanthine corresponds to the paraxanthine the body makes from roughly 135 mg to 154 mg of caffeine.

Benchmark Figure Source cited by TINA.org
Paraxanthine per Focus Pouch 100 mg Ultra label
Caffeine-equivalent per pouch About 135-154 mg TINA.org calculation from Lelo (1986) and Benowitz (1995)
Recommended daily caffeine ceiling, ages 12-18 100 mg American Academy of Pediatrics, via CDC
Ultra's daily limit for the Focus Pouch 4 pouches (400 mg paraxanthine, PPC Land calculation) Ultra label and product page
Rapid caffeine intake linked to toxic effects such as seizures About 1,200 mg FDA consumer update
Caffeine per Energy Pouch 180 mg Ultra, per TINA.org

On those numbers, a single Focus Pouch exceeds the pediatric ceiling, according to TINA.org. The group says a company TikTok video shows a user with ten or more pouches in his mouth, which would add up to at least 1,000 mg of paraxanthine, "roughly the amount the body produces from ingesting 1,350 to 1,540 mg of caffeine."

Marketing that reached minors

This is the part of the complaint that touches ad buying most directly. TINA.org says it started investigating after a reader reported that an Ultra ad "was running before YouTube videos likely to appeal to young viewers."

Search and video placements

On October 14, 2026, according to the complaint, a Google search for "what product can help my teen with adhd" returned a "Sponsored Products" unit with two Ultra listings, "Focus Pouches, Blue Razz" and "Focus Nootropic Pouches, Tropical," each priced at $16 and sold by Ultra Pouches.

A YouTube search for "how to survive high school with adhd" led to an "ADHD Student Guide" video, which played an Ultra pre-roll ad first. In that ad, Cantini says: "This looks like a nicotine pouch but it isn't. It's an Ultra, the world's first focus pouch. You pop one in, in about 10 minutes everything starts to quiet down and your mind gets sharper. Reclaim your focus at TakeUltra.com. And please always remember, focus responsibly." According to a footnote, searches for "u16baseball," a reference to under-16 youth baseball, and "legos" also led to YouTube videos preceded by Ultra pre-roll ads.

The same footnote adds a pointed aside for media buyers: "Of note, Google Ads allows advertisers to exclude ads from specific videos and channels." It cites Google's help pages on content suitability, content exclusions for video campaigns and demographic targeting. Google's content themes are the topic-level version of those controls. The complaint does not say how Ultra's campaigns were configured, and it does not allege that Google broke any rule.

Social posts and the "moms approve" ad

The complaint says Ultra ads "expressly tell consumers that its pouches are 'not 18+.'" In a TikTok video from October 16, 2025, Cantini describes the company this way, according to a footnote: "A way that we could put it is, like, if Zyn and Adderall had a baby - but it's all natural, it's not 18+. There's no caffeine in it. There's no nicotine in it. There's nootropics in it."

In one company Instagram post, a mother finds pouches belonging to her daughter. The daughter says, "They're Ultra Pouches, zero caffeine, zero nicotine. They're actually healthy, packed with nootropics and vitamins for focus." The mother replies, "Huh, well as long as you're not on Zyn." The caption reads: "Focus responsibly. With Ultra, even moms approve."

Affiliates, sponsorships and gaming creators

Ultra runs an affiliate program open to "[a]nyone passionate about Ultra's mission and products," according to the complaint. Affiliates earn commissions on sales, and their content goes further than the company's own. According to TINA.org, affiliates called the pouches "natural Addy" and "upper deck addy." One said, "Even a 13-year-old can have these." Another said, "Yes, you can bring these to school." Asked whether a 15-year-old could use a Focus Pouch, one affiliate answered: "Hell no. Because you should be taking two."

The complaint also names paid partners with large audiences.

Partner Audience cited What was said, per the complaint
Dak Prescott, Dallas Cowboys quarterback Not given "Nicotine wrecked my sleep, stole my focus, and zapped my energy, so I upgraded with Ultra." (Facebook post and ad, November 2, 2026; a version also runs on Ultra's homepage)
Nate Diaz, UFC fighter About 2.3 million Facebook and 7.2 million Instagram followers "Flow state. No crash. Ultra isn't energy. It's clarity." (paid partnership, December 27, 2025)
Ryguyrocky, Minecraft YouTuber Nearly 4 million subscribers Pouches are "100% safe" and "don't have caffeine"; video viewed more than 775,000 times (September 27, 2026)
Dignify2K, NBA 2K YouTuber More than 465,000 subscribers "It eliminates all that brain fog and kicks in in just five minutes." (August 1, 2026)
Anderson Independent Youth Soccer Association (AIYSA), Kentucky Children's soccer club Ultra logo on players' jerseys; Ultra listed as sponsor (fall 2026)

The complaint notes that Minecraft is rated "E10+ (Everyone 10+)" and NBA 2K "E" for Everyone by the ESRB, and cites Pew Research Center data that 85% of U.S. teens play video games, rising to 97% among teen boys. The creator videos carried discount codes: "apply RYGUYROCKY to get an additional 15% off the intro offer for up to 50% off your first order of ULTRA Pouches," reads the description under one video.

Two further footnotes touch disclosure. TINA.org says Ultra "may also be promoting its pouches through undisclosed partnerships," pointing to a Men's Journal Instagram Story that led to an article promoting Ultra "but does not disclose any material connection." It also says some Ultra ads carry a "Clinicians' Choice" badge "Verified by frontrowMD," stating that "Thousands of clinicians shared this with their patients without compensation." According to the complaint, FrontrowMD is "a marketing company whose badges reflect how many clinicians in its network have shared a product on their personal discount pages - a figure that is not evidence of the product's efficacy."

The label versus the marketing

The warning on the back of the Focus can reads, in full: "WARNING: This product is not recommended for children, pregnant, or lactating women and individuals sensitive to caffeine. Consume responsibly. Limit to 4 servings per day. Not recommended for use with caffeine or other stimulants. Choking hazard. Do not swallow pouch."

TINA.org argues that this language "rarely, if ever, appears on its website or in its other marketing materials," and that the marketing contradicts it. According to the complaint, Cantini told viewers he used "4-5 Ultra pouches everyday for over a year," and in another video ran the math on using six a day while acknowledging that "the suggested max of Ultra is four pouches a day." Ads show the pouches paired with coffee and a Celsius energy drink. One affiliate told viewers that if they had not tried "taking two of these at once with an energy drink in the morning, you are doing yourself a disservice."

The Focus Pouch is also sold for fasting. An Ultra Meta ad reads: "The hardest part of fasting isn't hunger. It's the brain fog that makes you useless by noon," followed by "16 HOURS. ZERO HUNGER." TINA.org links that pitch to research placing the peak age of onset for eating disorders between 14 and 19.

Where the science claims come from

Ultra's site uses several labels for its evidence: "scientifically proven," "clinically proven" and "backed by research." The numbers attached to those labels vary by page, according to the complaint.

Claim Page Fine print
"82% UltraFocus users saw improvement in their overall focus levels*" Science page, August 2026 "Results from a consumer perception surveys, conducted from November '24 through March '25 and March '26 to April '26, that included 100 customers who were taking Ultra for >30 days."
"90% Saw a significant improvement in their overall focus levels*" Intro Offer page, recorded by TINA.org November 6, 2026 "Results from a consumer perception survey, conducted from November '24 through March '25 that included 100 customers who were taking Ultra for >30 days."
"100+ Published studies on key research-grade nootropics + adaptogens, endorsed by neuroscientists" Science page None cited
">50 Published studies on Enfinity® PX and other key nootropic ingredients" Intro Offer page None cited
"Backed by 10+ years of research with 6 published and 3 ongoing studies." Ultra website None cited

According to TINA.org, Ultra has since removed the survey disclaimer from its Science page while keeping it on other pages. The group says consumer perception surveys "lack control groups, are not placebo-controlled and rely on subjective self-reports," and that nothing indicates whether the 100 participants had an ADHD diagnosis.

The complaint quotes the FTC's December 2022 Health Products Compliance Guidance: "Anecdotal evidence about the individual experiences of consumers, including surveys of consumer experiences, are never sufficient to substantiate claims about the effects of a health product."

On ingredient research, TINA.org lists six paraxanthine studies and says none supports Ultra's marketing. According to the complaint, two were safety studies in rats, bacteria or cells, and four were human trials sponsored or funded by Ingenious Ingredients, with 12, 13, 12 and 21 participants who swallowed paraxanthine rather than absorbing it through the mouth. "TINA.org is not aware of any studies examining the efficacy of paraxanthine - Ultra's key ingredient - when absorbed through the lining of the mouth," the group writes. It adds that it is "not aware of any published studies examining the product's (or paraxanthine's) safety for minors."

How the subscription checkout works, according to TINA.org

The fourth allegation concerns billing. TINA.org says Ultra enrolls buyers in a monthly subscription that renews until cancelled, a form of negative option billing, without the disclosure and consent that the Restore Online Shoppers' Confidence Act requires. The complaint describes the path in five steps.

  1. Product page. The only subscription reference above the "Try It Now" button is small gray print reading "3 Cans delivered every 4 Weeks." The page lists three cans at $48.00 crossed out to $31.20, with savings of $16.80, which works out to $10.40 a can against a $16 single-can price.
  2. "Shipping & Subscriptions" tab. Further terms sit below the button or behind a tab that must be clicked: "We want your subscription to work on your terms. You can pause, skip, or cancel at any time. Just be sure to make any changes before your next order is processed. Head to your Account page and click Manage Subscription whenever you need to adjust."
  3. Payment page. Subscription references sit in an "Order summary" drop-down below the payment fields on mobile, with the line "This order has a recurring charge for multiple items" and "Every 4 Weeks" beside each flavor.
  4. Footer policy. According to TINA.org, the fact that charges recur indefinitely appears only in a "500+-word Subscription Policy hyperlinked at the very bottom of the company's webpages."
  5. Pressure prompts. An Instagram story offered "TAKE 45% OFF YOUR ORDER" behind a countdown clock, and checkout pages showed "ONLY A FEW LEFT - ORDER SOON" and "Reserve your Ultras before we sell out again!" According to TINA.org, "nothing happens when the clock reaches 0:00." Regulators often class such prompts as a dark pattern.

The complaint quotes 12 consumer reviews from the Better Business Bureau and Trustpilot dated between July 8 and October 27, 2026. These are unverified consumer accounts. "Your subscription is renewed in the middle of the night (mine at 4:18am)," reads one from August 27, 2026. Another, from August 10, says the "manage subscription" tab "intentionally does not load."

Ultra's stated position, quoted in the complaint, is that users can cancel "at any time before [their] next billing date without penalty."

Ultra's side

Ultra did not respond to TINA.org's request for comment, according to the group's article. Its public materials make the company's case instead. The funding release describes pouches "designed to support top performers whenever they need a tactical boost - during deep work, travel, training, or evenings - without addiction, heart problems, or mystery chemicals." The homepage says the brand is "not saying you should quit nicotine, but it is addictive, restricts blood flow, and isn't optimized for peak performance."

The homepage lists 6 "clinically-studied nootropics" in the Focus formula, shows a 4.9 rating from "500+ REVIEWS" and says the brand has been "Featured on: The Joe Rogan Experience," "This Past Weekend with Theo Von" and "The Shawn Ryan Show." It carries the FDA disclaimer in its footer. In a YouTube Short quoted in the complaint, Cantini says that "there was one thing I promised me and my brother we wouldn't compromise, and it's safety."

Why this matters for advertisers

Much of the evidence in the complaint comes from ad platforms rather than from Ultra's own site: Google Shopping units, YouTube pre-roll, Instagram story ads, Meta ads, TikTok creator videos and an Amazon brand store. The complaint therefore documents the placements and partners around the advertiser, not only the advertiser's own pages.

Subscription billing is the most established enforcement track. The FTC sued JustAnswer in January 2026, alleging that a monthly fee shown in small print between the card fields and the "Confirm now" button failed ROSCA's clear-and-conspicuous standard. Instacart agreed to pay $60 million in December 2025 over fees and Instacart+ enrollment. The FTC's click-to-cancel rule was challenged by industry groups in October 2024 and vacated by the Eighth Circuit in July 2025; TINA.org's complaint relies on the statute, ROSCA, rather than on that rule. A telehealth advertiser faces a similar mix: the FTC and seven states filed an amended complaint against Hims & Hers on November 10 over privacy and billing practices, which the company denies.

Fake urgency has been penalized outside the United States. Australia's Federal Court ordered Emma Sleep to pay $15 million in April 2026 over countdown timers that reset instead of ending.

Platforms have been tightening their own rules on health claims. Amazon's updated claims policy, covered by PPC Land on November 16, lists claims that non-prescription products match prescription drugs among six prohibited claim types. Earlier in the year, Amazon gave supplement sellers a March 31 deadline to align listing claims with Supplement Facts panels. LegitScript data showed ads for unapproved peptides rising 208% in 2024, an indication of how much unapproved health marketing runs through paid channels.

On minors, Google consolidated its ad protections for children and teens into one policy in January 2025, and YouTube's COPPA audience-setting deadline arrived in April 2026. TikTok Shop barred minors from selling in creator videos in August 2026. The Ultra complaint raises a different question: what happens when an adult product's own ads, affiliates and sponsored creators tell under-18s the product is fine for them?

What the documents do not say

Neither letter states how much Ultra spent on advertising or how its Google and YouTube campaigns were targeted. The complaint gives no sales or revenue figure beyond the January claim of 1,000,000 cans. It does not quote any study Ultra may hold privately. And it does not say whether Ultra has changed any ad since the filing, although its homepage still led with "INSTANT FOCUS IN A POUCH" on November 18.

Key facts

  • Complainant: Truth in Advertising, Inc. (TINA.org), P.O. Box 927, Madison, CT 06443. Signed by Laura Smith, Legal Director, and Bonnie Patten, Executive Director.
  • Company: Nuro Pouches, Inc., doing business as Ultra, Inc., 25 Kent Ave., Brooklyn, NY 11249. Website takeultra.com. CEO and founder Eric Drymer; co-founder Nicola Cantini.
  • Documents: "Re: Unfair and Deceptive Marketing Campaign for Ultra Pouches," letter to the FTC and FDA dated November 17, 2026 (51 pages including 104 footnotes); "Re: Unfair and Deceptive Marketing by NYC-Based Nuro Pouches, Inc. d/b/a Ultra Inc.," letter to the New York State Attorney General and NYC DCWP dated November 17, 2026 (2 pages).
  • TINA.org article: "Zyn Meets Adderall? TINA.org Takes Action against Ultra's Deceptive Marketing," November 18, 2026, truthinadvertising.org/articles/zyn-meets-adderall-tina-org-takes-action-against-ultras-deceptive-marketing/
  • TINA.org database page: truthinadvertising.org/brands/ultra-pouches/, with evidence sets at truthinadvertising.org/evidence/ultra-reckless-marketing/ and truthinadvertising.org/evidence/ultra-checkout-process/
  • Statutes cited: 15 U.S.C. 45; 15 U.S.C. 8403 (ROSCA); 21 U.S.C. 321(ff)(2)(A)(i), 321(g)(1)(C), 331(d), 355(a); 21 C.F.R. 101.93(g)(2); N.Y. Gen. Bus. Law 349, 350, 527-a; N.Y.C. Rules tit. 6, 5-110 to 5-110.3.
  • Products: Ultra Focus Pouch (100 mg Enfinity paraxanthine, 15 pouches per can), Ultra Energy Pouch (180 mg caffeine), Ultra Sleep Pouch.
  • Funding: $11 million Series A, announced January 20, 2026, led by Left Lane Capital; corrected release issued January 21, 2026 via Business Wire.
  • Status: Requests for investigation. No regulator action is recorded in the documents. Ultra did not respond to TINA.org's request for comment.

Timeline

Summary

Who: Truth in Advertising (TINA.org), a nonprofit consumer group, filed complaints about Ultra, the trading name of Brooklyn-based Nuro Pouches, Inc., which was founded by CEO Eric Drymer and co-founder Nicola Cantini and raised $11 million in January 2026. The letters went to the FTC, the FDA, the New York State Attorney General and New York City's Department of Consumer and Worker Protection.

What: TINA.org alleges that Ultra markets its paraxanthine-based Focus Pouch as an ADHD treatment and Adderall substitute without FDA approval or adequate science, directs marketing to minors through ads, affiliates, gaming creators and a youth soccer sponsorship, encourages use beyond its four-a-day label limit and enrolls buyers in subscriptions that are poorly disclosed and hard to cancel. These are allegations; no regulator has made a finding.

When: The complaints are dated November 17, 2026. TINA.org published its article and database page on November 18, 2026.

Where: The marketing ran across Google sponsored products, YouTube pre-roll and Shorts, Instagram, Facebook, TikTok, Amazon and Ultra's own website, and the complaints were sent to federal regulators in Washington and to state and city officials in New York.

Why: TINA.org argues that a stimulant pouch absorbed through the mouth is not a dietary supplement, so its focus and ADHD claims make it an unapproved drug, and that the subscription flow breaks ROSCA. For marketers, the case shows how evidence from ad placements, creator deals and checkout design can end up in a regulatory complaint.